Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We continue to make very good progress on automating the imaging quantification as well, which will have significant benefit for the commercial product |
| These results show a path to improving our diagnostic imaging and to greater and more effective targeted delivery of our therapeutic constructs to tumors and other sites of macrophage and valve pathology |
| And we have a very flexible, adaptable molecule that has all sorts of really great advantages over what almost every other group out there is using |
| These strong early results support our hypotheses and provide excellent data in support of tilmanocept imaging as a biomarker of CD206 expression in joints of patients with RA |
| So the numbers, I think, are solid numbers in terms of the market potential and the growth curves even |
| And so we have this great opportunity to be able to really shake up the world in these therapeutic domains |
| In partnership with our excellent patent attorneys, we have an active IP protection strategy for the company that will provide needed protections and rights to both our current diagnostic and therapeutic agents as well as to our next-generation molecules and disease indications |
| That's one, and it's really strong |
| But indeed, we have the potential for a powerful therapeutic |
| And the data that we're bringing to the table so far are significantly better than anything I've seen out there |
| It was stated that the exciting perfect prediction and remarkable test responses were generated in that testing for the treatment |
| These filings will be significant inflection points and opportunities for licensing and partnering deals for the company |
| And to be fair to Norgine, it's been years in the making that researchers have produced publications that support what I just said is our belief, that Lymphoseek has advantages |
| We continue to make solid progress on our Phase IIb trial in rheumatoid arthritis comparing imaging to biopsy |
| But really, and again, to be honest, what I think, Mike Rosol, the place where you're in the best position to get the most bang for your buck is when you've completed the trials and have strong data in hand |
| So we're very good at making a lot happen with a little |
| We are proud of the progress we have made and the planning we are putting in place to benefit our associates and our shareholders here at Navidea |
| So we believe that we also have a potential powerful therapeutic in our hands, pardon the pun of hands |
| In fact, it's actually very inexpensive, and it's pretty good |
| But like those -- the first revenue generated may be pushed off a bit, but the numbers themselves and the trajectory, once it happens, we still stand by and believe because we have a good idea of the competitive landscape |
| But it might be that our -- if we take our very powerful imaging readout and combine it with some readily available and already validated clinical biomarkers, we might be able to improve our prediction capacity, in some circumstances, the upwards towards a sensitivity of 100, right, or perfect |
| The workflow for these trials is extremely well designed |
| And so we know that our -- that in the data so far, tilmanocept imaging is a very good predictor in the data so far of clinical outcome at 3 and 6 months |
| We do think there are advantages to it |
| This project has advanced significantly in the last year with results from 3 separate experiments showing that a novel construct created by Navidea has significant therapeutic potential to control leishmanial infections in mice |
| So that's really cool and promising |
| We and others, and there's a growing body of research that supports this, suspect or believe that there are advantages to Lymphoseek over this product that has really dominated the market in Europe for years |
| And so the opportunities there to help people to treat diseases is enormous |
| Really, it's no secret that the company has been in a resource limited environment, but we are optimistic that we'll have something to announce around capital infusion soon |
| To me, it seems quite outstanding |
| Statement |
|---|
| Because if the drug is not working, the patient's disease is not being treated, and this can lead to long-term health consequences, along with unnecessary high drug costs for ineffective therapies that also bring with them possible side effects |
| And in all that time, it appears we've not been able to generate any significant revenue |
| The decrease was primarily due to the 2021 partial recovery of debt previously written off in 2015, the 2021 receipt of reimbursement from Cardinal Health of certain research and development costs, decreased grant revenue relative to small business innovation research from NIH supporting Manocept development and decreased license revenue from transitional sales up to Manocept in Europe |
| Never going to be perfect across the world, across everybody, across all time |
| I think there's a great under-appreciation for this patent that you received on the M1/M2 reprogramming in the TAMs that I just felt the market appreciated it yet, and I don't know if many investors had appreciated it |
| And we've been, frankly, in a resource limited environment for a while now |
| It's rare in the United States, but in more tropical countries where the sandfly vectors are found, it is a common serious and potentially life-threatening disease |
| So there are these kind of extremes of the macrophage in the macrophage world |
Please consider a small donation if you think this website provides you with relevant information